EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody–Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next‐Generation Strategies Against Multidrug‐Resistant Bacterial Infections

Parvin Askari iD, Soudabeh Eshaghi, Leila Omidvar, Motahareh Mahi-Birjand iD

MicrobiologyOpen · 2026-02 · 15 (1)

DOI: 10.1002/mbo3.70234 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MicrobiologyOpen, online erschienen am 18.02.2026. Verfasst von Parvin Askari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacterial Infections, Immunoconjugates, Drug Resistance, Multiple, Bacterial. Die Arbeit nennt 261 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rise of multidrug‐resistant (MDR) bacterial pathogens presents a critical challenge to global health, highlighting the need for innovative therapeutic strategies beyond conventional antibiotics. Antibody–antibiotic conjugates (AACs) combine the high specificity of monoclonal antibodies with the potent bactericidal activity of antibiotics, offering targeted delivery to extracellular and intracellular bacteria while minimizing off‐target toxicity. The present review provides a comprehensive analysis of AAC development, including key components, such as antigen selection, antibody engineering, linker chemistry, antibiotic payload optimization, and bioconjugation strategies. We summarize the mechanistic principles underlying AAC‐mediated bacterial clearance, emphasizing targeted payload release, fragment crystallizable region of the antibody (Fc)‐mediated immune engagement, and intracellular delivery. The temporal evolution of AACs is examined, highlighting milestones from early proof‐of‐concept studies to modern site‐specific, humanized constructs and emerging bispecific or dual‐payload designs. Furthermore, clinical development is discussed, focusing on pharmacokinetics, pharmacodynamics, safety, efficacy, and regulatory considerations, for example, intracellular infections and biofilm‐associated infectious agents. Current challenges, including antigen heterogeneity, immunogenicity, linker‐payload optimization, and manufacturing scalability, are critically analyzed, alongside strategies for next‐generation AACs. Collectively, AACs represent a transformative platform for precision‐targeted antimicrobial therapy, bridging gaps left by conventional antibiotics and offering a promising approach to combating MDR bacterial infections and associated clinical complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsBacterial InfectionsImmunoconjugatesDrug Resistance, Multiple, BacterialAntibodies, MonoclonalHumansAnimalsBacteria

Stichwörter der Autor:innen

antibiotic payloadantibody–antibiotic conjugatesbioconjugationlinker chemistrymultidrug‐resistant bacteriatargeted antimicrobial therapy

Substanzen

Anti-Bacterial AgentsImmunoconjugatesAntibodies, Monoclonal

Autor:innen und Institutionen

  • Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
  • Clinical Research Development Unit (CRDU), Valiasr Hospital, Birjand University of Medical Sciences, Birjand, Iran.
  • Department of Clinical Pharmacy, School of Pharmacy, Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.

ORCID-Profile: Parvin Askari, Motahareh Mahi-Birjand

Zitieren

APA

Askari, P., Eshaghi, S., Omidvar, L., & Mahi-Birjand, M. (2026). Antibody–Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next‐Generation Strategies Against Multidrug‐Resistant Bacterial Infections. MicrobiologyOpen, 15(1). https://doi.org/10.1002/mbo3.70234

Vancouver

Askari P, Eshaghi S, Omidvar L, Mahi-Birjand M. Antibody–Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next‐Generation Strategies Against Multidrug‐Resistant Bacterial Infections. MicrobiologyOpen. 2026;15(1). doi:10.1002/mbo3.70234

BibTeX
@article{Askari2026,
  author = {Askari, Parvin and Eshaghi, Soudabeh and Omidvar, Leila and Mahi-Birjand, Motahareh},
  title = {Antibody–Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next‐Generation Strategies Against Multidrug‐Resistant Bacterial Infections},
  journal = {MicrobiologyOpen},
  year = {2026},
  volume = {15},
  number = {1},
  doi = {10.1002/mbo3.70234}
}
Kostenlos starten →